Neutrophil oxidative metabolism in Down syndrome patients with congenital heart defects

Environmental and Molecular Mutagenesis

Volumn 51, Issue 1, 2010, Pages 57-63

  Akinci, Ozlem ^a   Mihci, Ercan ^a   Tacoy, Sukran ^a   Kardelen, Firat ^a   Keser, Ibrahim ^a   Aslan, Mutay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Congenital heart disease; Down syndrome; Reactive oxygen species

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE;

AEROBIC METABOLISM; ARTICLE; CELL LEVEL; CELL METABOLISM; CHILD; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OXIDATION REDUCTION REACTION; PHENOTYPE; PROTEIN EXPRESSION; SCHOOL CHILD;

ANTIOXIDANTS; BLOTTING, WESTERN; CATALASE; CHILD; DOWN SYNDROME; FEMALE; GLUTATHIONE PEROXIDASE; HEART DEFECTS, CONGENITAL; HUMANS; HYDROGEN PEROXIDE; MALE; NEUTROPHILS; OXIDATION-REDUCTION; SUPEROXIDE DISMUTASE;

EID: 75149126136     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20511     Document Type: Article

References (34)

1. Aslan M, Canatan D. 2008. Modulation of redox pathways in neutrophils from sickle cell disease patients. Exp Hematol 36:1535-1544.
2. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. 2001. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 98:15215-15220.
3. Aslan M, Yucel G, Bozcuk H, Savas B. 1998. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. Cancer Immunol Immunother 47:176-181.
4. Barlow GM, Chen XN, Shi ZY, Lyons GE, Kurnit DM, Celle L, Spinner NB, Zackai E, Pettenati MJ, Van Riper AJ, Vekemans MJ, Mjaatvedt CH, Korenberg JR. 2001. Down syndrome congenital heart disease: A narrowed region and a candidate gene. Genet Med 3:91-101.
5. Björkstén B, Marklund S, Hägglöf B. 1984. Enzymes of leukocyte oxidative metabolism in Down's syndrome. Acta Paediatr Scand 73:97-101.
6. Buettner GR. 1993. The pecking order of free radicals and antioxidants: Lipid peroxidation, a tocopherol, and ascorbate. Arch Biochem Biophys 300:535-543.
7. Cedergren J, Follin P, Forslund T, Lindmark M, Sundqvist T, Skogh T. 2003. Inducible nitric oxide synthase (NOS II) is constitutive in human neutrophils. APMIS 111:963-968.
8. Clerch LB, Massaro D, Berkovich A. 1998. Molecular mechanisms of antioxidant enzyme expression in lung during exposure to and recovery from hyperoxia. Am J Physiol 274:L313-L319.
9. Crosti N, Bajer J, Gentile M, Resta G, Serra A. 1989. Catalase and glutathione peroxidase activity in cells with trisomy 21. Clin Genet 36:107-116.
10. Epperly MW, Defilippi S, Sikora C, Gretton J, Greenberger JS. 2002. Radioprotection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene. Mil Med 167:71-73.
11. Epstein CJ.Down syndrome, trisomy 21. 1989. In: Scriver CR,Beaudet AL,Sly WS,Valle D, editors. Metabolic Basis of Inherited Disease. New York: McGraw-Hill (pub.). pp 291-326.
12. Feaster WW, Kwok LW, Epstein CJ. 1977. Dosage effects for superoxide dismutase-1 in nucleated cells aneuploid for chromosome 21. Am J Hum Genet 29:563-570.
13. Frank L. 1985. Effects of oxygen on the newborn. Fed Proc 44:2328-2334.
14. Freeman BA, Crapo JD. 1981. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 256:10986-10992.
15. Freeman BA, Topolosky MK, Crapo JD. 1982. Hyperoxia increases oxygen radical production in rat lung homogenates. Arch Biochem Biophys 216:477-484.
16. Gabbianelli R, Kantar A, Oggiano N, Fiorini R, Falcioni G, Giorgi PL. 1993. Oxidative metabolism in polymorphonuclear granulocytes of children with trisomy 21. Minerva Pediatr 45:493-497.
17. Garcez ME, Peres W, Salvador M. 2005. Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin Proc 80:1607-1611.
18. Gidding SS, Stockman JA III. 1988. Effect of iron deficiency on tissue oxygen delivery in cyanotic congenital heart disease. Am J Cardiol 61:605-607.
19. Gonzalez MM, Madrid R, Arahuetes RM. 1995. Physiological changes in antioxidant defenses in fetal and neonatal rat liver. Reprod Fertil Dev 7:1375-1380.
20. Hook EB, Cross PK, Schreinemachers DM. 1983. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 249:2034-2038.
21. Huggon IC, Cook AC, Smeeton NC, Magee AG, Sharland GK. 2000. Atrioventricular septal defects diagnosed in fetal life: Associated cardiac and extra-cardiac abnormalities and outcome. J Am Coll Cardiol 36:593-601.
22. Jovanovic SV, Clements D, MacLeod K. 1998. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 25:1044-1048.
23. Kedziora J, Bartosz G. 1988. Down's syndrome: A pathology involving the lack of balance of reactive oxygen species. Free Radic Biol Med 4:317-330.
24. Kedziora J, Blaszczyk J, Sibinska E, Bartosz G. 1990. Down's syndrome: Increased enzymatic antioxidative defense is accompanied by decreased superoxide anion generation in blood. Hereditas 113:73-75.
25. Lyle R, Béna F, Gagos S, Gehrig C, Lopez G, Schinzel A, Lespinasse J, Bottani A, Dahoun S, Taine L, Doco-Fenzy M, Cornillet-Lefèbvre P, Pelet A, Lyonnet S, Toutain A, Colleaux L, Horst J, Kennerknecht I, Wakamatsu N, Descartes M, Franklin JC, Florentin-Arar L, Kitsiou S, Aÿt Yahya-Graison E, Costantine M, Sinet PM, Delabar JM, Antonarakis SE. 2009. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet 17:454-466.
26. Mosca RS, Hirsch JC, Bove EL. 2001.Congenital heart disease and cardiac tumors. In: Greenfield LJ, Mulholland MW,Oldham KT, editors. Surgery: Scientific Principles and Practice,3rd ed . Philadelphia: Lippincott Williams and Wilkins. p 1443.
27. Muchová J, Sustrová M, Garaiová I, Liptáková A, Blazícek P, Kvasnicka P, Pueschel S, Duracková Z. 2001. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 31:499-508.
28. Offer T, Russo A, Samuni A. 2000. The pro-oxidative activity of SOD, nitroxide SOD mimics. FASEB J 14:1215-1223.
29. Pallardó FV, Degan P, d'Ischia M, Kelly FJ, Zatterale A, Calzone R, Castello G, Fernandez-Delgado R, Dunster C, Lloret A, Manini P, Pisanti MA, Vuttariello E, Pagano G. 2006. Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 7:211-220.
30. Pastor MC, Sierra C, Doladé M, Navarro E, Brandi N, Cabré E, Mira A, Serés A. 1998. Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients. Clin Chem 44:924-929.
31. Peled-Kamar M, Lotem J, Wirguin I, Weiner L, Hermalin A, Groner Y. 1997. Oxidative stress mediates impairment of muscle function in transgenic mice with elevated level of wild-type Cu/Zn superoxide dismutase. Proc Natl Acad Sci USA 94:3883-3887.
32. Rhee SG, Yang KS, Kang SW, Woo HA, Chang TS. 2005. Controlled elimination of intracellular H(2)O(2): Regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid Redox Signal 7:619-626.
33. Saugstad OD. 1990. Oxygen toxicity in the neonatal period. Acta Pediatr Scand 79:881-892.
34. Weydert CJ, Zhang Y, Sun W, Waugh TA, Teoh ML, Andringa KK, Aykin-Burns N, Spitz DR, Smith BJ, Oberley LW. 2008. Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth. Free Radic Biol Med 44: 856.